RGTLFArgent BioPharma Limited

About Argent BioPharma Limited (RGTLF)

Argent BioPharma Limited (RGTLF) is a N/A company headquartered in Subiaco, WA, Australia whose shares trade over-the-counter on the Pink tier.

Argent BioPharma Limited (the “Company”) (ASX: RGT; OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma’s robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases

Products and services

CimetrA - SLE Lupus, Anti Inflammatory, SARS COVID 19 CannEpil - Refractory Epilepsy CogniCann - Dementia and Alzheimer’s

RGTLF key facts

Ticker symbol

RGTLF

Market tier

Pink

Headquarters

Subiaco, WA, Australia

Country of incorporation

AU

Year of incorporation

2005

Employees

40

Estimated market cap

$8.15M (as of May 13, 2025)

Shares outstanding

54,272,269

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Latest filing

Interim Financial Report (Dec 31, 2024)

Argent BioPharma Limited leadership

• Roby Reuven Zomer — Co-Founder, CEO, Executive Director
• Igor Bluvstein — CFO
• Rowan Harland — Company Secretary

Explore more: Pink stocks · OTC stocks starting with R